Welcome to our dedicated page for BridgeBio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BridgeBio Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BridgeBio Pharma's regulatory disclosures and financial reporting.
BridgeBio Pharma, Inc. (BBIO) announced a voluntary agreement with the U.S. government intended to expand access to its medicines and lower costs for American patients, particularly those with rare genetic diseases. As part of the agreement, BridgeBio plans to expand state Medicaid access to its currently marketed medicine via the GENEROUS Model, building on existing patient support programs such as ForgingBridges®, which can reduce qualifying patients’ out-of-pocket costs to as little as $0 per month.
BridgeBio states that it does not expect to be subject to future pricing mandates and that its pricing commitment for future medicines is expected to exclude products approved exclusively for orphan indications. The agreement does not affect coverage of Attruby through Medicare Part D or the ForgingBridges copay assistance program. The company also highlights three additional medicines under FDA review for rare genetic conditions, with priority review PDUFA dates in late 2026 and 2027.
BridgeBio Pharma, Inc. (BBIO) reported that Chief Executive Officer and director Neil Kumar filed a Form 4 disclosing open-market sales of a total of 44,980 shares of common stock on August 18–19, 2026. Some shares were sold directly and others were sold by the Kumar Haldea Family Irrevocable Trust, where he is a co‑trustee. The transactions were effected pursuant to a Rule 10b5-1 sales plan adopted on May 13, 2026, with reported weighted average sale prices in the low-to-mid $80s per share. After these transactions, separately reported indirect holdings include 3,568,447 shares held by the Kumar Haldea Revocable Trust and 750,000 shares held by the NK 2026 GRAT, with Kumar disclaiming beneficial ownership of certain trust-held shares except to the extent of his pecuniary interest.
BridgeBio Pharma, Inc. (BBIO) received a notice that the Kumar Haldea Family Irrevocable Trust plans to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares relate to a 03/26/2016 acquisition described as “Conversion Management Incentive Units.” A figure of $2,489,400.00 is listed for these 30,000 shares, and 195,487,474 common shares are shown as outstanding as of 08/19/2026 on NASDAQ. Over the prior three months, related 10b5‑1 sales are reported for Neil Kumar and related trusts, including multiple transactions of 20,000–34,980 shares of BBIO common stock with aggregate proceeds in the low‑ to mid‑million‑dollar range.
BridgeBio Pharma, Inc. (BBIO) reported that President and CFO Thomas Trimarchi had 22,781 shares of common stock withheld on August 16, 2026 to satisfy tax obligations related to the vesting of 41,194 RSU-based shares. After this tax-withholding disposition, he directly held 336,529 shares, which includes 116 shares acquired on August 14, 2026 through the company’s Employee Stock Purchase Plan.
BridgeBio Pharma, Inc. (BBIO) reported that its Chief Executive Officer, Neil Kumar, had 71,217 Restricted Stock Units (RSUs) convert into an equal number of shares of common stock on August 16, 2026. Corresponding RSU derivative positions were eliminated as the awards vested and settled into common shares.
To cover associated tax obligations from this vesting, 36,237 shares of common stock were delivered or withheld at a price of $79.86 per share. Following these transactions, indirect holdings reported include 515,686 shares held by the Kumar Haldea Family Irrevocable Trust, 3,568,447 shares held by the Kumar Haldea Revocable Trust, and 750,000 shares held by the NK 2026 GRAT, with the reporting person disclaiming beneficial ownership of these trust-held shares except to the extent of any pecuniary interest.
BridgeBio Pharma, Inc. (BBIO) reported that Chief Accounting Officer Maricel Apuli had 4,714 shares of common stock withheld on 2026-08-16 to satisfy tax obligations related to vesting of 9,262 RSU-based shares. After this tax-withholding disposition, Apuli directly holds 122,687 shares of BridgeBio common stock.
BridgeBio Pharma, Inc. (BBIO) received a notice that Neil Kumar intends to sell common stock under Rule 144. The filing lists 34,980 shares of common stock held through Morgan Stanley Smith Barney, with a reported value of $2,794,552.20, against 195,487,474 shares outstanding as of August 18, 2026. It also details prior Rule 10b5-1 plan sales over the past three months by Kumar and related trusts.
BridgeBio Pharma, Inc. common stock is the subject of this amended beneficial ownership report by KKR-affiliated entities. KKR Genetic Disorder L.P., as selling stockholder, entered into an underwriting agreement on August 13, 2026 with William Blair & Company, Goldman Sachs & Co. and KKR Capital Markets, covering an offering of 5,000,000 shares of common stock. The underwriters purchased these shares at a net price of $77.415 per share to KKR Genetic Disorder L.P., and the offering closed on August 17, 2026 under the issuer’s effective shelf registration.
After this transaction, KKR Genetic Disorder L.P. directly holds 8,260,971 shares of common stock, and the reporting group’s aggregate reported interest is 9,232,739 shares, including 971,768 shares issuable upon conversion or redemption of 133,900 shares of Series A Cumulative Convertible Participating Preferred Stock held by an alternative vehicle. This represents approximately 4.7% of BridgeBio’s common stock, based on 195,492,997 shares outstanding as of August 11, 2026, so the KKR reporting persons state they have ceased to be beneficial owners of more than five percent and characterize this amendment as an exit filing.
BridgeBio Pharma Inc. (symbol BBIO) reports a planned sale of 21,501 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $1,717,069.86, expected on August 17, 2026 on NASDAQ. The shares are to be sold in connection with an exercise of stock options, with the issuer listed as the party receiving cash for the option exercise.
During the prior three months, Randal Scott reported 10b5-1 plan sales of 2,196 shares of common stock on June 24, 2026 for total proceeds of $152,073.00.
BridgeBio Pharma, Inc. reported that existing shareholder KKR Genetic Disorder L.P. is conducting a secondary public offering of 5,000,000 shares of BridgeBio common stock. An Underwriting Agreement with William Blair & Company, Goldman Sachs & Co. LLC and KKR Capital Markets LLC covers the sale at a public offering price of $78.00 per share. The shares are being sold by the selling stockholder, and BridgeBio is not selling any shares and will not receive any of the proceeds. The offering is being made under an automatic shelf registration statement on Form S-3ASR, with the transaction expected to close on August 17, 2026, subject to customary conditions.